Spontaneous Bacterial Peritonitis Clinical Trial
Official title:
A Randomized Non-inferiority Trial Comparing Low Dose Albumin Versus Standard Dose Albumin in High Risk Spontaneous Bacterial Peritonitis.
AIM:- A randomized non-inferiority trial comparing low dose albumin versus standard dose albumin in high risk Spontaneous Bacterial Peritonitis. Methodology In this non-inferior randomized controlled trial one group will receive Low dose albumin: 20% albumin 0.75 g/kg at diagnosis and 0.5 g/kg after 48 hours and other group will receive Standard dose albumin: 20% albumin1.5 g/kg at diagnosis and 1 g/kg after 48 h (duration of infusion 6 hours). Study population: Patients of age > 18 years of age with cirrhosis of liver who are admitted in ward/Intensive Care Unit diagnosed with Spontaneous Bacterial Peritonitis. Study design: Randomized controlled trial Study period: September 2019- September 2020 Sample size: 300 (150 cases in each group) If there is a true difference in favour of the experimental treatment of 5 % then 270 patients are required to be 80% sure that the upper limit of a one sided 95% confidence interval (or equivalently a 90 % two-sided confidence interval) will exclude a difference in favour of the standard group of more than 5 %. And if the investigators consider 10% drop out final sample size is 270+30=300. 150 in each limb. Cases will be randomly allocated in 2 groups by block randomization method with block size taken as 10. Monitoring and assessment: all the parameters of the objective and also noted any adverse effects. Adverse Effects: Nausea, Vomiting, Fever with chills, dyspnea Stopping Rule: in the event of any of the adverse effects during therapy. Expected Outcome of the project: Proportion of patients having new development or progression of Acute Kidney Injury by day 7
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06026267 -
Efficacy of Conventional Dose Protocol vs Low Dose Protocol Albumin Use in Patients With Cirrhosis and High Risk Spontaneous Bacterial Peritonitis
|
N/A | |
Withdrawn |
NCT02552862 -
Study of the Effect of Adjunctive Vivomixx® in Patients With Cirrhosis and Spontaneous Bacterial Peritonitis (SBP)
|
Phase 3 | |
Completed |
NCT02528097 -
A Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis
|
N/A | |
Completed |
NCT01193426 -
Diagnostic of Spontaneous Bacterial Peritonitis
|
||
Completed |
NCT00359853 -
Norfloxacin In The Primary Prophylaxis Of Spontaneous Bacterial Peritonitis
|
Phase 4 | |
Active, not recruiting |
NCT04159870 -
Rifaximin Versus Norfloxacin in Spontaneous Bacterial Peritonitis
|
Phase 3 | |
Completed |
NCT04153604 -
Doxycycline for the Prevention of Spontaneous Bacterial Peritonitis
|
||
Completed |
NCT06234046 -
Rifaximin as a Prophylaxis of Spontaneous Bacterial Peritonitis in Comparison With Ciprofloxacin
|
Phase 3 | |
Recruiting |
NCT01598870 -
Diagnosis of Spontaneous Bacterial Peritonitis
|
N/A | |
Recruiting |
NCT00761098 -
Randomized Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis (SBP)
|
Phase 4 | |
Completed |
NCT05401721 -
Serum Copeptin in Cirrhotic Patients With Spontaneous Bacterial Peritonitis
|
||
Completed |
NCT02468089 -
To Compare the Efficacy of Carbepenem Versus Carbepenem Plus GM-CSF in Difficult To Treat Spontaneous Bacterial Peritonitis
|
N/A | |
Not yet recruiting |
NCT04746937 -
Nitazoxanide in Prevention of Secondary Spontaneous Peritonitis
|
Phase 3 | |
Recruiting |
NCT02759497 -
Evaluation of Serum Amyloid A in Early Diagnosis of Spontaneous Bacterial Peritonitis
|
N/A | |
Completed |
NCT02608658 -
Evaluation of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects With Decompensated Cirrhosis With Ascites
|
N/A | |
Completed |
NCT02388035 -
Cefotaxime Resistance in Treatment of Spontaneous Bacterial Peritonitis
|
N/A | |
Completed |
NCT03163745 -
Asymptomatic Spontaneous Bacterial Peritonitis in Patients With Decompensated Liver Cirrhosis
|
||
Active, not recruiting |
NCT04395365 -
Primary Antibiotic Prophylaxis Using Co-trimoxazole to Prevent Spontaneous Bacterial Peritonitis in Cirrhosis
|
Phase 3 | |
Terminated |
NCT00570960 -
Clinical, Inflammatory, and Economic Impact of Dextran 70 in Treating Spontaneous Bacterial Peritonitis
|
Phase 4 | |
Recruiting |
NCT05422118 -
Ascitic Fluid Calprotectin as an Accurate Diagnostic Marker for Spontaneous Bacterial Peritonitis
|
N/A |